In Truth on the Market, we argued that the FTC's personalized-pricing proposal overlooks the sales that tailored discounts make possible.

In Truth on the Market, we argued that a brain-injury blood test's 20-year road to patients shows why Congress must fix patent eligibility law.

In Truth on the Market, we argued that policymakers can't know enough about AI to regulate it well, so consumers, not bureaucrats, should steer it.

In The National Law Review, we argued that markets, not government mandates, should decide how to power the data centers behind American AI.